Hansa Biopharma to host conference call to provide interim results for the first quarter of 2020 and business update
Lund, Sweden April 15, 2020. Hansa Biopharma will publish its interim report for January-March 2020 at 8:00 a.m. CET on April 28, 2020. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 2:00 p.m. CET. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details provided below:
Dial-in numbers for participants:
SE: +46 8 50 55 83 54
UK: +44 333 300 92 69
US: +1 833 249 84 06
The webcast will be available on https://hansa.eventcdn.net/2020q1/
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Mobile: +46 (0) 709-298 269
About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.